How many investments has Atlas Venture made?

Atlas Venture has 139 tracked investments, 29 of which have exited, including 11 dated in the last 24 months.

What stage does Atlas Venture invest at?

Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.

What is Atlas Venture's typical check size?

Atlas Venture typically writes checks of $500K – $1M.

What sectors does Atlas Venture focus on?

Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Atlas Venture located?

Atlas Venture is headquartered in Cambridge, US.

Does Atlas Venture lead rounds?

Atlas Venture typically participates in rounds rather than leading them.

Who does Atlas Venture co-invest with?

Atlas Venture most often shares deals with Foresite Capital, OrbiMed, F-Prime Capital, among 68 tracked co-investors.

Atlas Venture

Venture capitalActively deployingoperating company · company profile

Cambridge · Seed–Late Stage · 29 people tracked

Also known as ATLAS VENTURE ADVISORS, INC. · Atlas Venture Ill · ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Atlas Venture

1,887 people in our graph share verified history with the Atlas Venture team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Kevin Bitterman · together at Harvard Medical School (overlapped)

×3knows the team · via Harvard University

knows the team · via Atlas Venture

knows the team · via Harvard Medical School

knows the team · via Genocea Biosciences

knows the team · via Remix Therapeutics

✨ Fox Verdict

Investment thesis

Atlas Venture focuses on medical and biotech innovation, backing early-stage life sciences companies. The firm operates an incubator through which it launches new startups, and its portfolio companies have developed approved medicines and achieved outcomes including IPOs and M&A exits. With roughly thirty years of experience, the firm positions itself at the leading edge of medical innovation.

Invests inBiotech Deep Tech Digital Health Healthtech Medical Devices Cambridge United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Late Stage

Check

$500K – $1M

Cambridge, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

1993

Last 12 months

4 investments

AUM

$3.2B

VC funds

Tracked investments

139

Unicorns

IPOs

Acquisitions

Team · 29 people

from the firm's website & curated & public directories

Dmitry Balyasny· General Partner

Jean-Francois Formela· General Partner· Boston, Massachusetts, United Statesin

Kristin Baker Spohn· General Partner

Rashmi Gopinath· General Partner

Bruce Booth· Partner· Wellesley, MAin 𝕏

Bruce Booth is a partner at Atlas Venture focused on the discovery and development of novel medicines and therapeutic platforms. He joined Atlas in 2005 after working as a consultant at McKinsey & Company and as an investor for Caxton Health Holdings. He holds a D.Phil. in molecular immunology from Oxford University, which he attended as a British Marshall Scholar, and a BS in biochemistry from The Pennsylvania State University.

b•••@atlasventure.comreveal

David Grayzel· Managing Director· Cambridge, Massachusetts, United Statesin

David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).

d•••@atlasventure.comreveal

Jason Rhodes· Partner· Cambridge, Massachusetts, United Statesin

Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.

j•••@atlasventure.comreveal

Jean-François Formela· Partner· Boston, Massachusetts, United Statesin

Jean-François Formela is a partner at Atlas Venture, where he focuses on novel drug discovery technologies and therapeutics. He joined the firm in 1993 to establish its U.S. life sciences practice. He holds an M.D. from Paris University School of Medicine and an M.B.A. from Columbia University.

j•••@atlasventure.comreveal

Kevin Bitterman· Partner· Cambridge, Massachusettsin 𝕏

Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.

k•••@atlasventure.comreveal

Michael Gladstone· Partner· Boston, Massachusettsin 𝕏

Michael Gladstone is a partner at Atlas Venture, which he joined in 2012, and works on forming new therapeutics companies. Before Atlas, he worked at L.E.K. Consulting on business development and corporate strategy for biopharma clients, and earlier led HIV vaccine research in the Viral Pathogenesis department at Beth Israel Deaconess Medical Center. He holds an AB in biochemical sciences from Harvard College.

m•••@atlasventure.comreveal

Peter Barrett· Partner· Massachusettsin

Peter Barrett has worked at Atlas Venture since 2002, helping create therapeutic and drug discovery platform companies. Before Atlas, he co-founded Celera Genomics, serving as executive vice president and chief business officer, and previously held senior management roles at Applera. He holds a BS in chemistry from Lowell Technological Institute (now UMass Lowell) and a PhD in analytical chemistry from Northeastern University.

p•••@atlasventure.comreveal

Aimee Raleigh· Principal· Boston, Massachusettsin 𝕏

Aimee Raleigh is a principal at Atlas Venture, where she works with founders building companies in therapeutics and biology. Before Atlas, she was a life sciences consultant at L.E.K. Consulting, advising pharmaceutical and biotech clients on strategy for early-stage therapies, asset diligence, and commercial planning. She holds a Ph.D. in bioengineering from the University of California, San Diego, and a B.S.E. in biomedical engineering from Duke University.

a•••@atlasventure.comreveal

Jernej Godec· Principal· New York City, NYin 𝕏

Jernej Godec is a Slovenian former competitive swimmer specializing in freestyle and butterfly who represented Slovenia at the 2004 Athens and 2008 Beijing Summer Olympics. He swam collegiately for the University of California, Berkeley while majoring in Molecular and Cell Biology, then earned a doctoral degree in Immunology at Harvard University, completing it in 2016. He held multiple Slovenian national records in sprint freestyle and butterfly events and won gold in the 50 m butterfly at the 2009 World University Games. He now lives in New York City.

j•••@atlasventure.comreveal

Maurizio Fazio· Principal· Cambridge, Massachusettsin 𝕏

Maurizio Fazio is a principal at Atlas Venture, where he works on building companies that turn scientific and technological advances into new therapeutics. He earned his PhD in biological and biomedical sciences at Harvard University, studying genetic and epigenetic drivers of melanoma progression in Leonard Zon's lab, and previously was a research fellow at Memorial Sloan Kettering Cancer Center investigating epigenetic therapies for pediatric leukemia. During graduate school he held fellowships at Vida Ventures and Flagship Pioneering and taught courses at the Harvard Summer School; he holds an MD from Vita-Salute San Raffaele University in Milan.

Phillip Samayoa· Venture Partner· Cambridge, Massachusetts, United Statesin

Phillip Samayoa is a venture partner with over 15 years of experience as a biotech investor, executive, and company builder. He most recently was chief scientific officer and chief strategy officer at Generation Bio, where he built business development, portfolio strategy, and discovery research functions and raised over $750M across financings and partnerships. He was previously a principal on the Atlas investment team, co-founded Generation Bio and Dyne Therapeutics, and earlier held roles at Merck's MRL Ventures Fund and Flagship Pioneering; he holds a Ph.D. in systems biology from UC San Diego and dual B.S. degrees from MIT.

John Maraganore· Venture Partner· Boston, Massachusetts, United Statesin

Founding CEO of Alnylam Pharmaceuticals, which he led from 2002-2021, overseeing the development and commercialization of the first RNAi medicines. He is currently CEO of JMM Innovations and serves on numerous biopharma boards; he holds an M.S. and Ph.D. in biochemistry and molecular biology from the University of Chicago.

Jodie Morrison· Venture Partner· Massachusettsin

Jodie Morrison serves as CEO and Board Member at Q32 Bio Inc., a biotechnology company. She also holds positions as a venture advisor at Atlas Venture and serves on biotechnology company boards.

Rajesh Devraj· Venture Partner· Cambridge, Massachusettsin 𝕏

Steven Robinette· Venture Partner𝕏

Julia Pian· Senior Associate· United Statesin 𝕏

Julia Pian is a senior associate at Atlas Venture, where she invests in and helps build companies developing novel therapies. Before joining the firm, she completed her pediatrics residency at Boston Children's Hospital and Boston Medical Center, and she continues to practice as a pediatric hospitalist at Boston Medical Center. She holds an AB in chemical and physical biology from Harvard College, an MD from Harvard Medical School, and an MBA from Harvard Business School.

Justin Feng· Senior Associate· Cambridge, Massachusetts, United Statesin

Justin Feng is a senior associate at Atlas Venture, where he invests in and helps build companies developing novel therapeutics. He previously was a senior associate at MRL Venture Funds (the corporate venture arm of Merck & Co.) and a senior manager on the Transactions and Early Innovation Partnering teams at Johnson & Johnson, and earlier served as a principal scientist at GRO Biosciences. He holds a BS with High Honors from UC Berkeley and a Ph.D. in biology from Harvard Medical School, completed in the lab of George Church as a National Science Foundation Graduate Fellow.

Stella Paffenholz· Senior Associate· Boston, Massachusetts, United Statesin

Stella Paffenholz is a senior associate at Atlas Venture, where she builds and invests in early-stage companies developing therapies from novel biology. She was previously a principal on the investment team at Nextech Invest, investing from Series A through public markets, and earlier held roles at McKinsey & Company, Apollo Health Ventures, and Merck KGaA. She holds a PhD from Memorial Sloan Kettering Cancer Center, where she studied genetic determinants of cancer treatment response, along with an MS from the German Cancer Research Center/University of Heidelberg and a BS from the University of Bonn.

Maksim Slyusarchuk· Executive Officer

Victor Kuznetsov· Executive Officer

Chelsea Johnson· Senior Associate· Boston / New Englandin 𝕏

c•••@atlasventure.comreveal

Ommer Chohan· CFO· Greater Bostonin

Ommer Chohan is the CFO of Atlas Venture, which he joined in 2015, where he oversees the firm's financial, legal, and operations functions. Before Atlas, he served as CFO/COO at Summerhill Venture Partners, joining in 2006 as part of the team that spun the firm out from Bell Canada, and earlier held the role of VP-Finance at First Asset Management Inc. He holds a BA in Management from the University of Toronto, an MBA from Cornell University's Johnson School, and a Master of Legal Studies in Taxation from Washington University in St. Louis, and earned his CPA (Ontario) while at PwC.

o•••@atlasventure.comreveal

Nello Mainolfi· Advisor· Greater Bostonin

Nello Mainolfi is the Founder, President, and Chief Executive Officer of Kymera Therapeutics (NASDAQ: KYMR). He has held leadership roles in both large pharmaceutical companies and smaller biotech firms, with experience in company creation, team building, strategic partnering, and private and public offerings. At Kymera, his work is focused on developing a class of degrader medicines.

Josh Powers· Associate· Boston, Massachusettsin

Sarah Downey

Founder mafia

The Atlas Venture mafia →

32 people who came through Atlas Venture went on to found or lead other companies.

Josh ResnickVenture PartnerFounded Synolo Therapeutics +3 Nessan BerminghamVenture PartnerFounded Korro Bio +2 Romesh SubramanianEntrepreneur In ResidenceFounded RaNA Therapeutics +2 Phillip SamayoaVenture PartnerFounded Generation Bio +2 Sumit AgarwalAssociateFounded Ariodata +2 Simon ReadVenture PartnerFounded Mariana Oncology +2 Henri MoissinacPrincipal, Internet and software in EuropeFounded TIER Mobility +1 Jason RhodesPartnerFounded Rectifypharma +1 Philip AustinAnalystFounded Enko Chem +1 Adam NashAssociate PartnerFounded Daffy +1 Mohamed GeneadStrategic & Scientific AdvisorFounded Aviceda Therapeutics +1 Andrew FraleyEntrepreneur In ResidenceFounded Korro Bio +1

+ 20 more

What they invest in

from 101 of 139 portfolio companies

Biotech ×75Healthtech ×49Medical Devices ×19Deep Tech ×14AI & Machine Learning ×13SaaS ×7Digital Health ×5Enterprise Software ×5

HQs:United States×84United Kingdom×2Azerbaijan×1Luxembourg×1

Who they back

founder profiles across 20 portfolio companies

30%

solo founders

6 of 20 mapped founding teams

26%

repeat founders

of 19 founders with career history

~2 yrs

old at investment

median across 19 dated deals

Founding team size:solo founder×62 founders×103 founders×24+ founders×2

Where their founders studiedfrom 14 founders with education data

Columbia University ×2Imperial College London ×2

What their founders studiedfrom 12 founders with field-of-study data

Chemistry ×4Life Sciences ×4Medicine ×4

Where their founders worked beforefrom 19 founders with career history

Massachusetts General Hospital ×2Omega Funds ×2Vectura Group plc. ×2

backed the same founder in 2+ companies: 2 founders

Investments · 139 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 7 2024 · 10 2023 · 7 2022 · 5 2021 · 9 2020 · 5 2019 · 7 2018 · 6 2017 · 4 2016 · 4 2015 · 790 dated

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTBSeries A · May 2020 · $46M✓ verified

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)in David Appugliese(Senior Vice President, Head of People)in

Co-investorsOrbiMed Agent Capital CU Healthcare Innovation Fund OUP (Osage University Partners)Sanofi Ventures 5AM Ventures +2 more

Sionnatxsionnatx.com in 𝕏NASDAQ: SION✓ verified

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsOrbiMed RA Capital

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)Jose Rivera(Executive Officer)in John Leonard(President and Chief Executive Officer)in James Basta(Executive Vice President, General Counsel and Corporate Secretary)in Edward Dulac(Executive Vice President, Chief Financial Officer)in

Board seat Jean-François Formela· per SEC Form D

Co-investorsage1 Avoro Capital Advisors EcoR1 Capital Foresite Capital OrbiMed Fidelity Investments

KALA BIOkalarx.com inNASDAQ: KALAAug 2015SEC filingmedium confidence

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Board seat Kevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude Capital SR One Capital Management Ysios Capital Lux Capital RA Capital Third Rock Ventures

Korro Biokorrobio.com in 𝕏NASDAQ: KRROSeed · May 2019 · $70M

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)in Jean-François Formela(Director)in Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)in Ram Aiyar(Chief Executive Officer, President and Director)in Todd Chappell(Chief Operating Officer)in

Board Jean-Francois Formela(Director)in

Board seat Jean-François Formela· per SEC Form D

Co-investorsMC Healthcare Ventures New Enterprise Associates (NEA)Alexandria Qiming Venture Partners USA Rock Springs Capital Taiwania Capital +1 more

Neuroneticsneurostar.com inNASDAQ: STIMApr 2015SEC filingmedium confidence

Neuronetics manufactures and sells the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation device used in office-based treatment of major depressive disorder and other mental health conditions, along with operating a network of treatment centers that provide both NeuroStar therapy and esketamine treatment to patients.

HealthtechMalvern, US

Mark R. Bausinger(Executive Officer)in Christopher Thatcher(Executive Officer, Director)inDaniel L. Reuvers(President and Chief Executive Officer)

BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)

Board seat Kevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015

Co-investors1315 Capital Ascension Ventures CHV Capital GE Ventures

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPROSeed · Jul 2021

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)in Stephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

Board Jean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)

Board seat Jean-François Formela· per SEC Form D

Co-investorsHEALTHCARE ROYALTY PARTNERS MRL Ventures Fund OUP (Osage University Partners)RA Capital Alphabet Fidelity Investments

Xilio Therapeuticsxiliotx.com inNASDAQ: XLOFeb 2021SEC filingmedium confidence

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Board seat David Grayzel· per SEC Form D · $95M raise · filed Feb 2021

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +9 more

Alnylamalnylam.com in 𝕏NASDAQ: ALNY

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

John Maraganore(Founder)inDr. Yvonne Greenstreet(Chief Executive Officer)inJeffrey V. Poulton(Executive Vice President and Chief Financial Officer)Bryan A. Supran(Executive Vice President, Chief Legal Officer and Secretary)in Pushkal Garg(Executive Vice President and Chief Research and Development Officer)inTolga Tanguler(Chief Commercial Officer)in

Co-investorsARCH Venture Partners Blackstone Life Sciences Cardinal Partners Invivo Capital Partners

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCSeed · Oct 2009

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)inKEVIN LEE(Executive Officer, Director)in NIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Longwood Fund SR One Capital Management SV Health Investors +2 more

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRONSep 2021 · $90M

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Bain Capital Life Sciences Foresite Capital Frazier Life Sciences OrbiMed 5AM Ventures +6 more

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(Chief Executive Officer and President, Director)in

Co-investorsMPM BioImpact Vida Ventures Forbion Hercules Capital, Inc.RA Capital

Exelixisexelixis.com in 𝕏NASDAQ: EXEL

Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types.

BiotechHealthtechSan Francisco Bay Area, US

Michael M. Morrissey(President and Chief Executive Officer)inChristopher J. Senner(Executive Vice President and Chief Financial Officer)

Johnson & Johnsonjnj.com in 𝕏NYSE: JNJ

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson I Joaquin Duato inJ. Duato(Chief Executive Officer)

Co-investorsAisling Capital NaviMed Capital Portland Seed Fund SPRINGROCK VENTURES The Column Group venBio Partners

Kymera Therapeuticskymeratx.com in 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in Bruce Booth(Chair)in

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Bessemer Venture Partners Hatteras Venture Partners MRL Ventures Fund Nextech Invest +6 more

miRagen TherapeuticsNASDAQ: VRDN

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.

BiotechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in

Co-investorsBrace Pharma MC Healthcare Ventures Boulder Ventures Heartland Remeditex Ventures

Replimunereplimune.com in 𝕏NASDAQ: REPL

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsBain Capital Life Sciences Foresite Capital REDMILE

Synlogicsynlogictx.com in 𝕏OTC: SYBXSeries A · Jul 2014 · $29M

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)in Paul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in

Co-investorsNew Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Sofinnova Ventures Solasta Ventures OrbiMed

Unum Therapeuticscogentbio.com in 𝕏NASDAQ: COGT

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.

BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)inAndrew Robbins(Chief Executive Officer, President and Director)inJohn Green(Chief Financial Officer)inEvan Kearns(Chief Legal Officer and Corporate Secretary)inCole Pinnow(Chief Commercial Officer)in

Co-investorsF-Prime Capital

Antares Therapeuticsantaresrx.com in 𝕏Series A · May 2025 · $180M✓ verified

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in

Board seat Jean-François Formela· per SEC Form D

Co-investorsLightspeed Venture Partners Vida Ventures Omega Funds Tenmile Abingworth AlleyCorp +1 more

Comanche Biopharmacomanchebiopharma.com inSeries B · Jan 2024 · $75M✓ verified

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)

Board Brendan Bulik-Sullivan(Director)in

Board seat David Grayzel· per SEC Form D

Co-investorsGV (Google Ventures)Broadview Ventures F-Prime Capital Lilly Asia Ventures New Enterprise Associates (NEA)

Ifmtheraifmthera.com in 𝕏Series A · Jun 2016 · $27M✓ verified

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.

BiotechHealthtechCambridge, US

Gary D. Glick(Founder)inH. Martin Seidel(Chief Executive Officer)in

Board Jean-Francois Formela(Director)in

Board seat Jean-François Formela· per SEC Form D

Co-investorsAbingworth

Kinaset Therapeuticskinasettherapeutics.com in 𝕏Jul 2022✓ verified

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

Board Jamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Board seat Kevin Bitterman· per SEC Form D

Co-investors5AM Ventures RA Capital EQT Life Sciences Sixty Degree Capital Vivo Capital Gimv +3 more

Remix Therapeuticsremixtx.com in 𝕏Jan 2024 · $70M✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)in Matthew Patterson(Director)in Scott Biller(Director)in

Board seat Kevin Bitterman· per SEC Form D

Co-investorsForesite Capital The Column Group ARCH Venture Partners Decheng Capital

Triana Biotrianabio.com in 𝕏Series A · Dec 2025 · $110M✓ verified

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Board seat David Grayzel· per SEC Form D

Co-investorsAscenta Capital Lightspeed Venture Partners RA Capital Bessemer Venture Partners Pfizer Ventures Pfizer Venture Investments +2 more

Calderatxcalderatx.com✓ verified

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsJanus Henderson Investors LAV venBio Partners

Curileumcurileum.com in✓ verified

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

Dr Jeff Moore(Founder & CEO)

Co-investorsBiotechnology Value Fund Canaan Partners Prospect Venture Partners Oxford Technology Management

Ethyrealbioethyrealbio.com in✓ verified

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.

BiotechHealthtechCambridge, US

Niranjan Kameswaran(Chief Executive Officer)inJessica Stromme(Chief Development Officer)inKelly Foster(Chief Scientific Officer)in Stephen Huang(Senior Vice President, Head of Clinical Development)in

Board Simon Read(Chairman of the Board and Independent Board Member)in

Co-investorsAvoro Capital Advisors Medicxi

Judo Biojudo.bio inSeries A · Oct 2024 · $75M✓ verified

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.

BiotechHealthtechCambridge, US

Andrew Fraley(Co-founder)inAlfica Sehgalin OMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho

Co-investorsDigitalis Ventures The Column Group Droia Ventures YK Bioventures

Lifordi Immunotherapeuticslifordi.comSeries A · Nov 2025 · $42M✓ verified

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtech

Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)

Co-investorsARCH Venture Partners Sanofi Ventures 5AM Ventures

nChroma Bionchromabio.com in 𝕏✓ verified

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhD Jonathan Weissman, PhD

Co-investorsNewpath Partners ARCH Venture Partners DCVC (Data Collective)F-Prime Capital GV (Google Ventures)5AM Ventures +2 more

Pheontxpheontx.com in✓ verified

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsBiotechnology Value Fund Forbion Lightspeed Venture Partners Research Corporation Technologies TCG Crossover

Rectifypharmarectifypharma.com in 𝕏Series A · Oct 2021 · $100M✓ verified

Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.

BiotechDeep Tech

Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)

Co-investorsDC Investment Partners Longwood Fund Forbion

Vima Therapeutics, Inc.vimatx.com inSeries A · May 2025 · $60M✓ verified

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.

BiotechHealthtechMedical Devices

Bernard Ravina(Founder and Chief Executive Officer)inJudy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)in Ariel D. Jasie(Chief Business Officer and General Counsel)in Tushar Misra(Chief Technical Officer)in

Co-investorsFrazier Life Sciences Access Industries Access Biotechnology Canaan Partners

Affinia Therapeuticsaffiniatx.com inSeries A · Oct 2025 · $60M

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)

Board seat David Grayzel· per SEC Form D

Co-investorsEcoR1 Capital Eight Roads Ventures F-Prime Capital GV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover +1 more

Day One Biopharmaceuticalsdayonebio.com in 𝕏Series A · Feb 2021 · $60M

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

Board Derek DiRocco(Director)inJulie Papanek Grant(Director)in John Josey(Director)inDaniel Becker(Director)

Board seat Michael Gladstone· per SEC Form D

Co-investorsAccess Biotechnology Canaan Partners Access Industries RA Capital The Column Group

Grobiogrobio.com in 𝕏Jul 2024SEC filingmedium confidence

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Board seat Kevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024

Co-investorsLeaps by Bayer REDMILE Digitalis Ventures Dreamers VC Rising Tide Access Industries +2 more

Navitor Pharmaceuticalsnavitorpharma.com inDec 2015

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in

Board Jean-Francois Formela(Director)in Alan Crane(Director)Marian Nakada(Director)in Brian Gallagher(Director)in

Board seat Kevin Bitterman Jean-François Formela· per SEC Form D

Co-investorsage1 Brace Pharma Sanofi Ventures Polaris Partners SR One Capital Management

RaNA Therapeutics inJul 2015

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)

Board seat Jean-François Formela· per SEC Form D

Co-investorsPfizer Venture Investments

Renasant Biorenasantbio.com in 𝕏Jul 2025 · $55M

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).

BiotechHealthtechBerkeley, US

Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)in Emily Conley(Executive Officer, Director)in

Board Evan Caplan(Director)inCharlotte McKee(Director)

Board seat Kevin Bitterman· per SEC Form D

Co-investors5AM Ventures OrbiMed Qiming Venture Partners USA

Scorpion Therapeuticsscorpiontx.comSeries A · Jul 2024 · $110M

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)in Darrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Board seat Jean-François Formela· per SEC Form D

Co-investorsAvoro Capital Advisors EcoR1 Capital Frazier Life Sciences Nextech Invest Vida Ventures Abingworth +3 more

AAVantgarde Bioaavantgarde.comSeries A · Jun 2023 · $65M

Co-investorsNeva Sgr.Sofinnova Partners XGEN Venture Forbion Longwood Fund

Accent Therapeuticsaccenttx.com in 𝕏Series A · Jan 2024 · $40M

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsDroia Ventures EcoR1 Capital GV (Google Ventures)The Column Group JJDC Johnson & Johnson Innovation – JJDC +1 more

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsForesite Capital Frazier Life Sciences Scion Life Sciences The Innovation Space venBio Partners Versant Ventures

Arkuda Therapeuticsarkudatx.com inSeries A · Feb 2022 · $64M

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsMission Biocapital Pfizer Venture Investments Pfizer Ventures Pivotal Life Sciences

BE Biopharmabe.bioSeries A · Oct 2020 · $52M

Co-investorsAlta Partners ARCH Venture Partners DC Investment Partners Longwood Fund Nextech Invest Pathway to Cures+6 more

Becomebecome.co in 𝕏Series A · Sep 2004 · $5M

Become provides a technology platform that matches small and medium-sized businesses with tailored funding options using advanced algorithms.

FintechMarketplacesSaaS

Co-investorsEntrée Capital

Bluespecbluespec.com in 𝕏Jan 2012

Bluespec develops tools and IP for hardware and embedded systems developers, with a focus on RISC-V technology for core evaluation, software development, acceleration, and verification.

Deep TechDeveloper ToolsHardwareSemiconductorsFramingham, US

Arvind Mithal(Director)Charles Hauck, Jr.(Executive Officer, Director)Paul Pedevillano(Executive Officer)in Charlie Hauck(Chief Executive Officer)inBrian McAloon(Director)Dave Lemont(Director)in

Co-investorsAccomplice North Bridge Venture Partners

Bluetrainbluetrainmobile.com

The site presents a multi-day conference about application and web design, covering design theory, tools, product design roles, and current web design trends.

Media & Entertainment

Co-investorsBantam Group Boston Seed Capital LaunchCapital

Carbon Blackcarbonblack.comFeb 2014

Waltham, US

Patrick Morley(Executive Officer, Director)inEric Pyenson(Executive Officer)Gordon Pothier(Executive Officer)

BoardRonald Nordin(Director)Jeff Fagnan(Director)Paul Maeder(Director)in

Co-investors.406 Ventures Accomplice Evolution Equity Partners Founders Circle Capital Intel Capital Kleiner Perkins +5 more

CloudSwitchverizon.com in 𝕏

Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.

Cloud ComputingEnterprise SoftwareNew York, US

Co-investorsMatrix North Atlantic Capital Norwest Venture Partners

Clypdclypd.com

Advertising technology platform providing audience-based sales for television advertising.

Somerville, US

Joshua Summers(Executive Officer, Director, Promoter)Doug Hurd(Executive Officer, Director, Promoter)

BoardRyan Moore(Director)Lars Albright(Director)in

Co-investorsBoston Seed Capital Transmedia Capital Tribeca Venture Partners Data Point Capital Freestyle Capital Western Technology Investment

CustomMadecustommade.com in 𝕏

CustomMade is a custom jewelry design and creation service that works with clients to create bespoke pieces, including bridal, heirloom redesign, and fine jewelry.

B2B MarketplacesConsumerDirect to ConsumerE-commerceDover, US

Seth Rosen(Executive Officer, Director)in

BoardDavid Hauser(Director)Sasha Shusteff(Director)

Co-investorsFirst Round Capital Founder Collective GV (Google Ventures)Launch Capital NextView Ventures Schooner Capital

Deepscaledeepscale.aiSeed · Mar 2017 · $3M

Mountain View, US

Sri Chandrasekar(Director)Forrest Iandola(Executive Officer, Director)Kurt Keutzer(Director)

Co-investorsAutotech Ventures Trucks VC 11.2 Capital Cota Capital

Diagonaltxdiagonaltx.com in

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Co-investorsEcoR1 Capital Frazier Life Sciences Sanofi Ventures

DisplayLinkdisplaylink.com in

DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.

Enterprise SoftwareHardwareSemiconductors

Co-investorsBalderton Capital Dag Ventures Cipio Partners Prelude Ventures

docTrackrdoctrackr.com in

CybersecurityCambridge, US

Co-investorsBantam Group Techstars

Earnestearnest.ag in 𝕏

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.

AgTechBiotechRantoul, US

Eddy Mejia(Co-founder)inDr. Gabe Price(Co-founder)

Co-investorsAg Ventures Alliance AgLaunch Accelerator Boot64 Ventures Adams Street Partners Andreessen Horowitz Battery Ventures +4 more

Egaletegalet.comJan 2019

Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products.

BiotechHealthtechMedical DevicesWayne, US

BARBARA A. CARLIN(SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER)ROBERT S. RADIE(CHIEF EXECUTIVE OFFICER)MARK STROBECK(EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER)MEGAN TIMMINS(SENIOR VICE PRESIDENT AND GENERAL COUNSEL)PATRICK M. SHEA(SENIOR VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER)Jeffrey M. Dayno(Chief Medical Officer)

Co-investorsSunstone Capital

EnglishCentralenglishcentral.com inSeed · Oct 2009 · $1M

EnglishCentral is an online English language learning platform offering videos and courses for learners.

AI & Machine LearningEdTechSaaS

Alan Schwartz(Founder & CEO)inIan Park(President & Board Member)

Co-investorsBantam Group Valor Capital Group

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Aerovate Therapeutics, Inc.Akero Therapeutics, Inc.Akriveia Therapeutics Amagma, Inc.Antegrin Therapeutics Caldera Therapeutics, Inc.Chroma Medicine, Inc.Direct Vet Marketing Euclises Pharmaceuticals IFM Cinque IFM Continua IFM Quattro IFM Tre Ikena Oncology, Inc.Morphic Holding, Inc.AavantgardebioAppcitoCadent TherapeuticsCaptricityCogent BiosciencesDeliniaDiagonal TherapeuticsEthyreal BioF StarFlashnotes Gemini TherapeuticsHarbour AntibodiesInMoji LTG Exam Prep Platform Magenta Therapeutics Mnemosyne PharmaceuticalsNimbus TherapeuticsObsidian TherapeuticsOverdogPheon TherapeuticsQuench BioRaze TherapeuticsSionna TherapeuticsTrace NeuroscienceTranslate BioTriplet Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 29

19 IPOs · 10 acquisitions · showing 26

Q32 BioNASDAQ: QTTBSionnatxNASDAQ: SIONIntellia TherapeuticsNASDAQ: NTLAKALA BIONASDAQ: KALAKorro BioNASDAQ: KRRONeuroneticsNASDAQ: STIMSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLOAlnylamNASDAQ: ALNYBicycleNASDAQ: BCYCDisc MedicineNASDAQ: IRONDyne TherapeuticsNASDAQ: DYNExelixisNASDAQ: EXELJohnson & JohnsonNYSE: JNJKymera TherapeuticsNASDAQ: KYMRmiRagen TherapeuticsNASDAQ: VRDNReplimuneNASDAQ: REPLSynlogicOTC: SYBXUnum TherapeuticsNASDAQ: COGTDeliniaacq. by CelgeneGrabCADacq. by StratasysHorizon Therapeuticsacq. by AmgenKinveyacq. by Progress SoftwareMorphosysacq. by NovartisOverdogacq. by Odd NetworksTranslate Bioacq. by Sanofi

Portfolio news

latest coverage across their companies

H.C. Wainwright raises Spero Therapeutics price target to $6 By Investing.com

Spero · investing.com · Sep 14, 2026

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | BioPharma Dive

Nimbus · biopharmadive.com · Sep 11, 2026

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Disc Medicine · prnewswire.com · Aug 18, 2026

Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

Spero Therapeutics · marketbeat.com · Aug 18, 2026

Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Simply Wall St News

Intellia Therapeutics · simplywall.st · Aug 18, 2026

Neuronetics director Jorey Chernett buys $44,240 in company stock By Investing.com

Neuronetics · investing.com · Aug 17, 2026

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law | Press Releases | daily-tribune.com

Exelixis · daily-tribune.com · Aug 16, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

IPO stake values · per SEC filings · 4

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Dyne Therapeutics	18.9%	$28.00	Jan 2021	$273M
Replimune	14.4%	$15.00	Jul 2018	$66.8M
Sionnatx	8.5%	$18.00	Feb 2025	$65.4M
Spero Therapeutics	5.7%	$12.50	Jul 2018	$12.9M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

1 insider ownership filing (Forms 3/4/5)

at Q32 Bio Inc. (QTTB)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Atlas Venture made?: Atlas Venture has 139 tracked investments, 29 of which have exited, including 11 dated in the last 24 months.
What stage does Atlas Venture invest at?: Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.
What is Atlas Venture's typical check size?: Atlas Venture typically writes checks of $500K – $1M.
What sectors does Atlas Venture focus on?: Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Atlas Venture located?: Atlas Venture is headquartered in Cambridge, US.
Does Atlas Venture lead rounds?: Atlas Venture typically participates in rounds rather than leading them.
Who does Atlas Venture co-invest with?: Atlas Venture most often shares deals with Foresite Capital, OrbiMed, F-Prime Capital, among 68 tracked co-investors.

Co-investors · 127

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 14

Dyne Therapeutics KALA BIO Sionnatx Spero Therapeutics Xilio Therapeutics Day One Biopharmaceuticals Kinaset Therapeutics Mariana Oncology Nimbus Triana BioDiagonal TherapeuticsNimbus TherapeuticsObsidian TherapeuticsTrace Neuroscience

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 12

Disc Medicine Intellia Therapeutics Q32 Bio Sionnatx Synlogic Gemini Therapeutics Ikena Oncology, Inc.Ikenaoncology Renasant Bio TriveniSionna TherapeuticsThird Harmonic Bio

$1M – $75M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 9

Accent Therapeutics Affinia Therapeutics Comanche Biopharma CustomMade Magenta Therapeutics nChroma Bio Nimbus Rodin TherapeuticsTrace Neuroscience

$250K – $50M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 8

Unum Therapeutics Xilio Therapeutics Affinia Therapeutics Akriveia Therapeutics Comanche Biopharma Generation Bio K36 Therapeutics nChroma Bio

$3M – $10M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 8

Kymera Therapeutics Synlogic Arkuda Therapeutics RaNA Therapeutics Triana BioNimbus TherapeuticsTriplet Therapeuticsvisit www.nimbustx.com

$5M – $20M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 7

Kymera Therapeutics Q32 Bio Diagonaltx Lifordi Immunotherapeutics Matchpoint Therapeutics Navitor PharmaceuticalsMatchpointtx

$5M

The Column Group

The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.

Both backed · 7

Johnson & Johnson Accent Therapeutics Day One Biopharmaceuticals Judo Bio Remix TherapeuticsBE BiopharmaThumbnail for Immune Design

$30M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Both backed · 7

Disc Medicine Intellia TherapeuticsReplimuneAkero Generation Bio Ikena Oncology, Inc.Remix Therapeutics

Omega Funds

Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.

Both backed · 7

Antares Therapeutics Caldera Therapeutics, Inc.Ikena Oncology, Inc.Lysosomal Therapeutics Morphic Holding, Inc.nChroma Bio Scorpion Therapeutics

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 6

Alnylam Lifordi Immunotherapeutics nChroma Bio Remix TherapeuticsBE BiopharmaNimbus Therapeutics

$50K – $250M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 6

Disc Medicine Q32 Bio Kinaset Therapeutics Lifordi Immunotherapeutics nChroma Bio Renasant Bio

$100K – $4M

Access Industries

Access Industries is a private holding company and global investment firm founded in 1986 by Len Blavatnik that identifies companies with strong business models and management teams to optimize their value through financial backing and strategic expertise.

Both backed · 6

Day One Biopharmaceuticals Grobio Magenta Therapeutics Mariana Oncology Matchpoint Therapeutics Vima Therapeutics, Inc.

▶115 more co-investors

Longwood Fund Lightspeed Venture Partners New Enterprise Associates (NEA)SR One Capital Management Forbion venBio Partners SV Health Investors Nextech Invest Accomplice Third Rock Ventures Digitalis Ventures Hatteras Venture Partners Vida Ventures Canaan Partners Polaris Partners Sofinnova Partners Bessemer Venture Partners First Round Capital Vivo Capital Leaps by Bayer Andreessen Horowitz Sequoia Capital Founder Collective DCVC (Data Collective)Innovation Endeavors Kapor Capital Cota Capital Entrée Capital AlleyCorp GE Ventures EQT Life Sciences Founders Circle Capital Johnson & Johnson Innovation – JJDC MPM BioImpact Autotech Ventures Pivotal Life Sciences Novartis Venture Fund Andera Partners Ysios Capital Roche Venture Fund Borealis Ventures Broadview Ventures ACORN BIOVENTURES Aditum Bio General Catalyst Craft Ventures Accel Greylock Partners Index Ventures Redpoint Ventures Uncork Capital Felicis Ventures SV Angel Menlo Ventures BoxGroup CRV (Charles River Ventures)DST Global ACME Capital FirstMark Capital Slow Ventures HCVC AME Cloud Ventures Accel-KKR Stride VC Practical Venture Capital Crosslink Capital Point Nine Pareto Holdings Entrepreneur First General Atlantic HV Capital Passion Capital Wildcat Venture Partners 83North Peak Breakthrough Energy Ventures FELIX CAPITAL Capital Factory Walden International LocalGlobe MMC Ventures Hoxton Ventures Blue Owl Capital Playground Global Motier Ventures NGP Capital Highbury Holdings BIOSPRING PARTNERS 20VC IrishAngels Angel Invest Jigsaw VC Mangrove Capital Partners Episode1 Kima Ventures Motivate Venture Capital Day One Ventures Pillar VC Allen Institute for Artificial Intelligence Incubator (AI2)AlbionVC Haatch Kurma Partners Signal Peak Ventures Axeleo Capital Beyond Capital Advent Life Sciences New Leaf Venture Partners Cornerstone VC Journey Ventures JMI Equity Fortino Capital Idinvest Partners Sherpa Ventures Altitude Ventures Management, Llc Nest.Bio Ventures

Firms observed investing alongside Atlas Venture, from public investor directories. Shared companies are the overlap with Atlas Venture's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

Venrock

Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.

$500K – $10M

JAZZ Venture Partners

JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.

$100K – $20M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M

OUP (Osage University Partners)

OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.

$1M – $20M